Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT‐2 study

AIM: To examine the long‐term efficacy and safety of dapagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor used to treat type 1 diabetes, in the Japanese subpopulation of the DEPICT‐2 study. MATERIALS AND METHODS: Patients with type 1 diabetes were randomized to dapagliflozin 5 mg (n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Eiichi, Mathieu, Chantal, Shiraiwa, Toshihiko, Maeda, Hajime, Ikeda, Hiroki, Thoren, Fredrik, Arya, Niki, Asano, Michiko, Iqbal, Nayyar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251623/
https://www.ncbi.nlm.nih.gov/pubmed/33620762
http://dx.doi.org/10.1111/dom.14362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251623/
https://www.ncbi.nlm.nih.gov/pubmed/33620762
http://dx.doi.org/10.1111/dom.14362

Ejemplares similares